Altimmune, Inc. (LON:0A4C)

Market Cap	424.96M +7.2%
Revenue (ttm)	14.88K -61.5%
Net Income	-62.43M
EPS	-0.79
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,500
Average Volume	3,287
Open	5.39
Previous Close	5.87
Day's Range	5.39 - 5.39
52-Week Range	3.68 - 6.30
Beta	n/a
RSI	47.41
Earnings Date	Feb 27, 2026

About Altimmune

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1997
• Employees: 59
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0A4C

Financial Performance

In 2024, Altimmune's revenue was $20,000, a decrease of -95.31% compared to the previous year's $426,000. Losses were -$95.06 million, 7.48% more than in 2023.

Financial numbers in USD